Traws Pharma, Inc. TRAW
0.23 USD -0.03 (-10.27%)
Regular-session close
0.24 +0.01 +2.91%
After hours · Nov 17, 5:58 PM ET
0.2333 Day range 0.2787
0.22 52-week range 3.23
- YTD
- -79.35%
- 1 year
- -88.78%
Benzinga news
benzinga.com Traws Pharma Q3 EPS $(0.18) Beats $(0.20) Estimate Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 47.06 percent increase over losses of $(0.34)…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.benzinga.com Traws Pharma Reports Final Phase 2a COVID-19 Data, Advances Influenza Candidate Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28…
benzinga.com Traws Pharma Enters $50M Committed Equity Purchase Agreement With Roth Principal Investments; May Issue And Sell Up To 135,135,135 Shares Of Common Stock Traws Pharma, Inc.Up to 135,135,135 Shares of Common StockThis prospectus relates to the resale by Roth Principal Investments, LLC, a Delaware limited liability company ("Roth Principal Investments"…
